US Patent 7629347 Protein tyrosine kinase inhibitors
Patent 7629347 was granted and assigned to Critical Outcome Technologies, Inc. on December, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 17 Sep, 2023
Golden AI
Edits made to:
Infobox (+7 properties)
Infobox
Patent Inventor Names
George Ma0
Ghenadie Rusu0
Jianhua Zhong0
Martyn Brown0
Natalie Lazarowych0
Stephen Houldsworth0
Wayne R. Danter0
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Article (+280 characters)
Article
Patent abstract
The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signaling, the compounds represented as:
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07629347 Protein tyrosine kinase inhibitors US Patent 7629347 Protein tyrosine kinase inhibitors
Infobox
Patent Number
076293470
Patent Number
76293470
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076293470
Date of Patent
December 8, 2009
0Patent Application Number
105311070
Date Filed
October 9, 2003
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07629347 Protein tyrosine kinase inhibitors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07629347
Date of patent
December 8, 2009
Patent application number
10531107
Date Filed
October 9, 2003
Patent primary examiner
Find more entities like US Patent 7629347 Protein tyrosine kinase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
